| 4.22 0.11 (2.68%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.96  |
1-year : | 5.79 |
| Resists | First : | 4.24 |
Second : | 4.96 |
| Pivot price | 3.84 |
|||
| Supports | First : | 3.4 |
Second : | 2.88 |
| MAs | MA(5) : | 4.11 |
MA(20) : | 3.65 |
| MA(100) : | 5.25  |
MA(250) : | 8.73 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 92.8 |
D(3) : | 91.6 |
| RSI | RSI(14): 62.8 |
|||
| 52-week | High : | 18.5 | Low : | 2.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EVAX ] has closed below upper band by 19.6%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.25 - 4.27 | 4.27 - 4.29 |
| Low: | 4.07 - 4.08 | 4.08 - 4.1 |
| Close: | 4.19 - 4.22 | 4.22 - 4.25 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Wed, 17 Apr 2024
Evaxion reports progress in EVX-01 phase 2 melanoma trial By Investing.com - Investing.com Nigeria
Wed, 17 Apr 2024
Evaxion Biotech Advances Personalized Cancer Vaccine - TipRanks.com - TipRanks
Thu, 04 Apr 2024
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data - MSN
Wed, 03 Apr 2024
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 03 Apr 2024
Evaxion Biotech A/S (NASDAQ:EVAX): Are Analysts Optimistic? - Simply Wall St
Tue, 02 Apr 2024
Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -9 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.22e+006 (%) |
| Held by Institutions | 3.613e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -8.11 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 978 % |
| Return on Equity (ttm) | -79.5 % |
| Qtrly Rev. Growth | 238.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.92 |
| Qtrly Earnings Growth | -2.18e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 42580 |
| Forward Dividend | 27520 |
| Dividend Yield | 1009000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|